Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

KRAS mutations are among the most common genetic alterations in lung, colorectal, and
pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit …

Summary KRAS G12C was recently identified to be potentially druggable by allele-specific
covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP) …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

Cancer is a devastating disease process that touches the lives of millions worldwide.
Despite advances in our understanding of the genomic architecture of cancers and the …

Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those
targeting the MAPK pathway. Covalent inhibitors of KRAS p. G12C allele allow for direct and …

Over the past decade, rapid advances in genomics, proteomics and functional genomics
technologies that enable in-depth interrogation of cancer genomes and proteomes and high …

KRAS represents an excellent therapeutic target in lung cancer, the most commonly mutated
form of which can now be blocked using KRAS-G12C mutant-specific inhibitory trial drugs …

Cetuximab is a monoclonal antibody that is effective in the treatment of metastatic colorectal
cancer (mCRC). Cetuximab blocks epidermal growth factor receptor (EGFR)-ligand …

We are witnessing several revolutionary technological advances in cancer. These
innovations have not only contributed to a growing understanding of the tumor and its …